By Austin Roberts, Operations Manager, Sterile Fill-Finish, PCI Pharma Services
Protecting drug products from contamination is a critical step during the manufacture of vaccines and other biologics delivered parenterally. Ensuring particulate and bioburden control, as well as uncompromised sterility, has led to the development of aseptic transfer and containment methods for clinical and commercial sterile injectable products. However, these processes can extend manufacturing timelines and increase costs.
As robotic processing is emerging as a popular method for the primary filling of ready-to-use (RTU) containers, such as vials, syringes and cartridges, robotic aseptic fill ill-finish technology and the use of isolator-barrier systems are key to keeping pace with these requirements.
Robotic processing is expediting the filling process with automation while increasing accuracy, helping to speed life-changing, high-value drug products through the clinical pipeline with efficiency and speed. Examine how robotic technologies are poised to increase manufacturing flexibility and minimize risk as you aim to bring your biologic to market.